Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.
The aim of this study was to investigate the capacity of oral and parenteral therapeutic immunization to reduce the bacterial colonization in the stomach after experimental Helicobacter pylori infection, and to evaluate whether any specific immune responses are related to such reduction. C57BL/6 mice were infected with H. pylori and thereafter immunized with H. pylori lysate either orally together with cholera toxin or intraperitoneally (i.p.) together with alum using immunization protocols that previously have provided prophylactic protection. The effect of the immunizations on H. pylori infection was determined by quantitative culture of H. pylori from the mouse stomach. Mucosal and systemic antibody responses were analyzed by ELISA in saponin extracted gastric tissue and serum, respectively, and mucosal CD4+ T cell responses by an antigen specific proliferation assay. Supernatants from the proliferating CD4+ T cells were analyzed for Th1 and Th2 cytokines. The oral, but not the parenteral therapeutic immunization induced significant decrease in H. pylori colonization compared to control infected mice. The oral immunization resulted in markedly elevated levels of serum IgG+M as well as gastric IgA antibodies against H. pylori antigen and also increased H. pylori specific mucosal CD4+ T cell proliferation with a Th1 cytokine profile. Although the parenteral immunization induced dramatic increases in H. pylori specific serum antibody titers, no increases in mucosal antibody or cellular immune responses were observed after the i.p. immunization compared to control infected mice. These findings suggest that H. pylori specific mucosal immune responses with a Th1 profile may provide therapeutic protection against H. pylori.
Nyström
Johanna
J
Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Göteborg University, Box 435, 405 30 Göteborg, Sweden. johanna.nystrom@microbio.gu.se
Raghavan
S
S
Svennerholm
A-M
AM
D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood / Q000378:metabolism; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology; D015169:Colony Count, Microbial; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D016481:Helicobacter Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D016480:Helicobacter pylori / Q000254:growth & development* / Q000276:immunology; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D007071:Immunoglobulin A, Secretory / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D013270:Stomach / Q000276:immunology / Q000382:microbiology*; D013601:T-Lymphocytes / Q000276:immunology
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D016207:Cytokines; D007071:Immunoglobulin A, Secretory; D002772:Cholera Toxin